ProtaGene
ProtaGene is a privately held CRO providing advanced analytical services — including protein characterization, biosimilar comparability, gene therapy vector analytics, and integration site analysis — to biopharmaceutical developers and cell and gene therapy innovators across Europe and North America.
- Company typePrivate
- Founded2021
- HeadquartersHeilbronn, Germany
- Headcount51–100
- GTM typeB2B
- OfferingServices
What ProtaGene does
ProtaGene is a privately held contract research organization (CRO) headquartered in Heilbronn, Germany, with additional operations in Dortmund and Heidelberg (Germany) and Burlington, Massachusetts. The company delivers advanced analytical services to biopharmaceutical developers and cell and gene therapy (CGT) innovators, spanning protein biotherapeutic characterization, biosimilar comparability studies, gene therapy vector analytics, integration site analysis (ISA), molecular bioanalysis, gene expression quantitation, and commercial patient testing for approved advanced therapy medicinal products (ATMPs). Its two interconnected service lines — Biologic Drug Analytics and Cell & Gene Therapeutic Analytics — are supported by an Analytical Systems platform built on Thermo Q Exactive and Orbitrap mass spectrometers, Bruker QTOF instruments, HPLC and SPR systems, and Illumina MiSeq and Oxford Nanopore sequencing platforms.
ProtaGene operates a project-based, quote-driven professional services model, including a multi-year Customized-Candidate Analytical Development (C-CAD) strategic partnering program that assigns a dedicated CMC Molecule Manager to coordinate end-to-end analytical responsibility from candidate selection through commercialization. The company maintains GMP certification (since 2006 at its German sites, with US expansion forthcoming), GLP accreditation at Heidelberg (2024), GCLP and GCP compliance, CLIA registration in Massachusetts, and IVDR Article 5(5) conformity for two ISA components (May 2025). Its proprietary methods — notably LAM-PCR for vector integration site analysis, originated by GeneWerk co-founders Dr. Manfred Schmidt and Prof. Dr. Christof von Kalle, and S-EPTS/LM-PCR for gene editing safety assessment — are deeply embedded in regulatory submissions for approved gene therapies, including historical work on Glybera, the first approved gene therapy in a Western country.
ProtaGene traces its lineage to Protagen GbR (1997 spin-out from Ruhr-University Bochum), BioAnalytix (2012, Barnett Institute), and GeneWerk (founded 2014 by Schmidt, von Kalle, and Annette Deichmann). The current entity was formed by the 2016 merger of Protagen Protein Services with BioAnalytix, the July 2021 merger with GeneWerk, and the January 2022 rebranding to ProtaGene. Ampersand Capital Partners, which first backed GeneWerk in 2019, made an additional investment in November 2023 to support further expansion. The company sells through enterprise field sales and strategic partnerships, most recently signing a strategic partnership with Merck Life Science announced for May 2026 to broaden biologics testing solutions.
ProtaGene firmographics
Firmographics- Name
- ProtaGene
- Legal name
- ProtaGene Group
- Website
- https://protagene.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- ProtaGene is a privately held CRO providing advanced analytical services — including protein characterization, biosimilar comparability, gene therapy vector analytics, and integration site analysis — to biopharmaceutical developers and cell and gene therapy innovators across Europe and North America.
- Ownership category
- akta.pro rank
Where ProtaGene is headquartered
LocationHeadquarters
- HQ city
- Heilbronn
- HQ country
- Germany
- HQ region
- Europe
Offices4 records
Markets served
ProtaGene business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Contract Research Services: Project-based analytical testing and characterization services for biopharmaceutical and cell/gene therapy developers. Services span from research through commercial product release, including GMP lot release testing, stability testing, and regulatory submission support.
- Strategic Program Partnering (C-CAD): Customized-Candidate Analytical Development partnerships providing end-to-end analytical development responsibility from candidate to market, with dedicated CMC Molecule Manager coordination.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
ProtaGene product offering
Product offeringCore offering
ProtaGene is a contract research organization providing advanced analytical laboratory services for biopharmaceutical and cell/gene therapy developers. The company offers two integrated service lines — Biologic Drug Analytics (biotherapeutic characterization, product and process development, manufacturing and QC, biosimilar program support, clinical sample in vivo CQA mapping, and cell-based assays) and Cell & Gene Therapeutic Analytics (molecular bioanalysis, integration site analysis, vector analytics, long-read sequencing, bioinformatics, genome and gene editing analysis, gene expression analysis, and commercial patient testing) — delivered through GMP-, GLP-, GCP-, GCLP-, and CLIA-certified facilities across Germany and the United States.
Product overview
ProtaGene is a world-leading CRO providing advanced, integrated, and complete analytical solutions for the biopharmaceutical and cell & gene therapy industries. The company operates two interconnected service lines: Biologic Drug Analytics (encompassing Biotherapeutic Characterization Services, Product and Process Development, Manufacturing and QC, Biosimilar Program Support, Clinical Sample In Vivo CQA Mapping, and Cell-based Assays) and Cell & Gene Therapeutic Analytics (encompassing Molecular Bioanalysis, Integration Site Analysis, Vector Analytics, Long-Read Sequencing Services, Bioinformatics, Genome and Gene Editing Analysis, Gene Expression Analysis, and Commercial Patient Testing). Supporting these service lines are Analytical Systems and the C-CAD strategic partnership program. The organization was established in 2021 through the merger of Protagen Protein Services, BioAnalytix, and GeneWerk, operating four sites in Germany (Heilbronn, Dortmund, Heidelberg) and the USA (Burlington, MA).
Differentiator
Problem solved
Functional benefit
Products and services
- Biologic Drug Analytics Integrated analytical service line providing advanced analytics and complete data packages for all stages of biotherapeutic development (including biotherapeutic characterization, product and process development, manufacturing and QC, biosimilar program support, clinical sample in vivo CQA mapping, and cell-based assays) for biopharmaceutical developers from early discovery through commercial product release.
- Cell & Gene Therapeutic Analytics Integrated analytical development service line for gene therapy and cell therapy programs, combining molecular bioanalysis, viral vector characterization, integration site analysis, long-read sequencing, bioinformatics, genome and gene editing analysis, gene expression analysis, and commercial patient testing from discovery through clinical trials and post-marketing safety monitoring.
- Commercial Patient Testing Patient sample testing in support of safety monitoring protocols for approved gene therapy products, including Integration Site Analysis (ISA) and Vector Copy Number (VCN) testing performed at CLIA-certified sites for sponsors of approved ATMPs.
- Customized-Candidate Analytical Development (C-CAD) Strategic partnership program providing full responsibility and coordination for analytical programs across all stages of molecule development from clone to clinic to market, with a dedicated CMC Molecule Manager coordinating end-to-end analytical development for clients seeking comprehensive program partnering.
Quantifiable outcome
- Over 25 biosimilar molecules successfully supported for clients
- +1 more outcomes
Companies that use ProtaGene
Customer profileSegments3 records
Ideal customer profiles3 records
ProtaGene technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
ProtaGene partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Merck Life SciencestrategicStrategic partnership announced to expand comprehensive biologics testing solutions. The partnership combines ProtaGene's analytical expertise with Merck's life science business capabilities to provide enhanced service offerings for biologics developers.
Scale indicators5 records
Recent moves8 records
Expansion highlights6 records
ProtaGene competitors and assessment
Company assessmentEmerging players
- ABL Bio: ABL Bio is a specialized gene therapy CDMO/CRO offering viral vector manufacturing, biosafety testing, and integration site analysis services. Comparable to ProtaGene on cell/gene therapy analytics, with deeper manufacturing integration but narrower biotherapeutic protein characterization offerings.
- GenScript ProBio: GenScript ProBio provides CDMO and analytical services for biologics and cell/gene therapy developers, including vector characterization and biosafety testing. Comparable to ProtaGene on gene therapy and biologics analytics with growing specialty depth, particularly in viral vector and plasmid analytics.
- WuXi AppTec (WuXi Advanced Therapies Unit): WuXi AppTec's Advanced Therapies unit provides analytical testing and CMC services for cell and gene therapy developers, including viral vector characterization and biosafety testing. Comparable to ProtaGene on gene therapy analytics, with broader CDMO scale but less specialization in ISA and biosimilar comparability.
Broad incumbents
- Labcorp Drug Development (formerly Covance): Labcorp Drug Development offers central lab, bioanalytical, and biologics characterization services with global lab infrastructure. Competes with ProtaGene on protein characterization and biosimilar comparability work, but with substantially broader clinical and central lab services and less ISA specialization.
- Thermo Fisher Scientific (PPD Bioanalytical): Thermo Fisher Scientific acquired PPD and operates bioanalytical and biologics characterization labs that overlap with ProtaGene's mass spectrometry, GMP testing, and biosimilar characterization services. Has broader life sciences scale and instrument manufacturer position, but less focus on gene therapy ISA.
- Intertek Pharmaceutical Services: Intertek Pharmaceutical Services provides analytical development, GMP testing, and biologics characterization across global labs. Comparable to ProtaGene on biologics and biosimilar testing services, though with less specialization in cell/gene therapy integration site analysis.
- Eurofins BioPharma Product Testing: Eurofins BioPharma Product Testing is the largest global contract testing network for biopharmaceuticals, offering biologics characterization, biosimilar comparability, viral clearance, and cell/gene therapy analytics. Overlaps with ProtaGene across nearly all service lines at greater scale and broader geographic reach, though it is a portfolio rather than specialty provider.
- Charles River Laboratories: Charles River's Biologics and Cell & Gene Therapy CDMO/CRO services include analytical method development, biosafety testing, viral clearance, and cell therapy characterization. Competes with ProtaGene on biologics characterization and cell/gene therapy analytics, with deeper CDMO integration but less specialization in ISA and biosimilar comparability.
- SGS Health Sciences: SGS Health Sciences provides bioanalytical, biosafety, and biopharmaceutical characterization services from a global laboratory network. Overlaps with ProtaGene on biologics testing, GMP release, and biosafety testing, though at broader scale with less focus on gene therapy ISA.
Direct peers
- BioReliance (MilliporeSigma): BioReliance, the biopharma biosafety testing arm of MilliporeSigma (Merck KGaA), offers biosafety, viral clearance, and biologics characterization services including integration site analysis. Direct competitor to ProtaGene's Cell & Gene Therapy Analytics line, particularly on ISA, viral vector testing, and GMP lot release services for biologics developers.
Market position
Strengths2 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
ProtaGene social profiles
Digital presenceProtaGene compliance and trust
Trust signalCompliance8 records
ProtaGene financial estimates
Financial estimateRevenue estimate
Valuation estimate
ProtaGene leadership team
Management profileNumber of profiles
Profiles7 records
ProtaGene funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ProtaGene M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ProtaGene
What does ProtaGene do?
ProtaGene is a contract research organization providing advanced analytical laboratory services for biopharmaceutical and cell/gene therapy developers. The company offers two integrated service lines — Biologic Drug Analytics (biotherapeutic characterization, product and process development, manufacturing and QC, biosimilar program support, clinical sample in vivo CQA mapping, and cell-based assays) and Cell & Gene Therapeutic Analytics (molecular bioanalysis, integration site analysis, vector analytics, long-read sequencing, bioinformatics, genome and gene editing analysis, gene expression analysis, and commercial patient testing) — delivered through GMP-, GLP-, GCP-, GCLP-, and CLIA-certified facilities across Germany and the United States.
Is ProtaGene a public or private company?
ProtaGene is a private company. It is classified as venture growth investor backed and is currently operating.
When was ProtaGene founded?
ProtaGene was founded in 2021. It employs 51 to 100 people.
Where is ProtaGene based?
ProtaGene is headquartered in Heilbronn, Germany, in the Europe region.
How does ProtaGene make money?
Two revenue lines are on record. Contract Research Services are the primary driver. The others are strategic Program Partnering (C-CAD).
Who are ProtaGene's main competitors?
Emerging players on record are ABL Bio, GenScript ProBio and WuXi AppTec (WuXi Advanced Therapies Unit). Broad incumbents are Labcorp Drug Development (formerly Covance), Thermo Fisher Scientific (PPD Bioanalytical), Intertek Pharmaceutical Services, Eurofins BioPharma Product Testing, Charles River Laboratories and SGS Health Sciences. BioReliance (MilliporeSigma) is listed as a direct peer.
Does ProtaGene have an API?
No public API is recorded for ProtaGene.